申请人:NewLink Genetics Corporation
公开号:US20140066625A1
公开(公告)日:2014-03-06
Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleanine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.
目前提供IDO抑制剂及其制药组合物,用于调节吲哚胺2,3-双加氧酶的活性;治疗吲哚胺2,3-双加氧酶(IDO)介导的免疫抑制;治疗受益于抑制吲哚胺-2,3-双加氧酶酶活性的医疗状况;增强包括给予抗癌药物在内的抗癌治疗的有效性;治疗与癌症相关的肿瘤特异性免疫抑制;以及治疗与传染病相关的免疫抑制。